Cardiology Topics
RSSArticles
-
Cerebral Embolic Protection Device Disappoints in TAVR/Stroke Trial
In this largest-to-date randomized trial of stroke prevention in transcatheter aortic valve replacement patients, use of the Sentinel cerebral embolic protection device did not significantly affect the incidence of periprocedural stroke.
-
Poor Cardiovascular Health a Predictor for Premature Brain Aging
Worse cardiovascular health at age 36 years can predict worse brain aging and associated cognitive problems later in life.
-
Statins Plus Ezetimibe vs. Statins Alone
A comparison of rosuvastatin 10 mg/day plus ezetimibe (10 mg/day) to 20 mg/day of rosuvastatin alone showed non-inferiority in three-year major cardiovascular outcomes, with lower LDL cholesterol levels and fewer episodes of drug discontinuation or dose reductions in the combination therapy group.
-
Understanding Statin-Related Muscle Pain and Cardiovascular Benefits
A review of large-scale, randomized, double-blind trials of statin therapy suggested statins are responsible for only a small excess of muscle pain symptoms in patients taking these drugs.
-
Where Are the P Waves?
The ECG in the figure was obtained from a previously healthy young woman with “palpitations.” How would one interpret this two-lead rhythm strip? Is there a conduction disorder?
-
Lack of EP Evaluation of Chest Pain Can Lead to Disaster
If an emergency physician never evaluates such a patient, leaving the care solely to a physician assistant or a nurse practitioner, this could lay the foundation for litigation.
-
Preventing Strokes After Transcatheter Aortic Valve Replacement
Researchers continue testing cerebral embolic protection devices as a solution — but are they effective?
-
Irregular Sleep Could Cause More Inflammation
Those who slept few hours per night exhibited troubling signs of improper immune system function in a small study.
-
REVIVED Shows No PCI Benefit for Patients with Coronary Disease, Reduced EF
Researchers randomly assigned patients with an ejection fraction ≤ 35% and severe coronary disease to percutaneous coronary intervention or optimal medical therapy alone. After 3.4 years median follow-up, researchers noted no significant differences between groups in terms of all-cause death or heart failure hospitalization.
-
Statins Plus Ezetimibe vs. Statins Alone
A comparison of rosuvastatin 10 mg/day plus ezetimibe (10 mg/day) to 20 mg/day of rosuvastatin alone showed non-inferiority in three-year major cardiovascular outcomes, with lower LDL cholesterol levels and fewer episodes of drug discontinuation or dose reductions in the combination therapy group.